Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU): Resulting drug levels and modulation of oxylipin pattern

Annika I. Ostermann, Jan Herbers, Ina Willenberg, Rongjun Chen, Sung Hee Hwang, Robert Greite, Christophe Morisseau, Faikah Gueler, Bruce D. Hammock, Nils Helge Schebb

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Epoxides from polyunsaturated fatty acids (PUFAs) are potent lipid mediators. In vivo stabilization of these epoxides by blockade of the soluble epoxide hydrolase (sEH) leads to anti-inflammatory, analgesic and normotensive effects. Therefore, sEH inhibitors (sEHi) are a promising new class of drugs. Herein, we characterized pharmacokinetic (PK) and pharmacodynamic properties of a commercially available potent sEHi 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU). Cell culture studies suggest its high absorption and metabolic stability. Following administration in drinking water to rats (0.2, 1, and 5. mg TPPU/L with 0.2% PEG400), TPPU's blood concentration increased dose dependently within the treatment period to reach an almost steady state after 8 days. TPPU was found in all the tissues tested. The linoleic epoxide/diol ratios in most tissues were dose dependently increased, indicating significant sEH inhibition. Overall, administration of TPPU with the drinking water led to systemic distribution as well as high drug levels and thus makes chronic sEH inhibition studies possible.

Original languageEnglish (US)
JournalProstaglandins and Other Lipid Mediators
DOIs
StateAccepted/In press - Feb 27 2015

Fingerprint

Oxylipins
Epoxide Hydrolases
Rodentia
Epoxy Compounds
Modulation
Drinking Water
Pharmaceutical Preparations
Pharmacodynamics
Tissue
Pharmacokinetics
Non-Steroidal Anti-Inflammatory Agents
Unsaturated Fatty Acids
Cell culture
Rats
Blood
Stabilization
Cell Culture Techniques
Lipids
N-phenylurea

Keywords

  • Caco-2 intestinal absorption
  • EETs
  • Eicosanoids
  • Epoxy fatty acids
  • Oxylipins
  • Primary rat hepatocytes
  • Soluble epoxide hydrolase

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Pharmacology
  • Cell Biology

Cite this

Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU) : Resulting drug levels and modulation of oxylipin pattern. / Ostermann, Annika I.; Herbers, Jan; Willenberg, Ina; Chen, Rongjun; Hwang, Sung Hee; Greite, Robert; Morisseau, Christophe; Gueler, Faikah; Hammock, Bruce D.; Schebb, Nils Helge.

In: Prostaglandins and Other Lipid Mediators, 27.02.2015.

Research output: Contribution to journalArticle

Ostermann, Annika I. ; Herbers, Jan ; Willenberg, Ina ; Chen, Rongjun ; Hwang, Sung Hee ; Greite, Robert ; Morisseau, Christophe ; Gueler, Faikah ; Hammock, Bruce D. ; Schebb, Nils Helge. / Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU) : Resulting drug levels and modulation of oxylipin pattern. In: Prostaglandins and Other Lipid Mediators. 2015.
@article{a71a4afb2d74440287e90bdf3e16d903,
title = "Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU): Resulting drug levels and modulation of oxylipin pattern",
abstract = "Epoxides from polyunsaturated fatty acids (PUFAs) are potent lipid mediators. In vivo stabilization of these epoxides by blockade of the soluble epoxide hydrolase (sEH) leads to anti-inflammatory, analgesic and normotensive effects. Therefore, sEH inhibitors (sEHi) are a promising new class of drugs. Herein, we characterized pharmacokinetic (PK) and pharmacodynamic properties of a commercially available potent sEHi 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU). Cell culture studies suggest its high absorption and metabolic stability. Following administration in drinking water to rats (0.2, 1, and 5. mg TPPU/L with 0.2{\%} PEG400), TPPU's blood concentration increased dose dependently within the treatment period to reach an almost steady state after 8 days. TPPU was found in all the tissues tested. The linoleic epoxide/diol ratios in most tissues were dose dependently increased, indicating significant sEH inhibition. Overall, administration of TPPU with the drinking water led to systemic distribution as well as high drug levels and thus makes chronic sEH inhibition studies possible.",
keywords = "Caco-2 intestinal absorption, EETs, Eicosanoids, Epoxy fatty acids, Oxylipins, Primary rat hepatocytes, Soluble epoxide hydrolase",
author = "Ostermann, {Annika I.} and Jan Herbers and Ina Willenberg and Rongjun Chen and Hwang, {Sung Hee} and Robert Greite and Christophe Morisseau and Faikah Gueler and Hammock, {Bruce D.} and Schebb, {Nils Helge}",
year = "2015",
month = "2",
day = "27",
doi = "10.1016/j.prostaglandins.2015.06.005",
language = "English (US)",
journal = "Prostaglandins and Other Lipid Mediators",
issn = "1098-8823",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU)

T2 - Resulting drug levels and modulation of oxylipin pattern

AU - Ostermann, Annika I.

AU - Herbers, Jan

AU - Willenberg, Ina

AU - Chen, Rongjun

AU - Hwang, Sung Hee

AU - Greite, Robert

AU - Morisseau, Christophe

AU - Gueler, Faikah

AU - Hammock, Bruce D.

AU - Schebb, Nils Helge

PY - 2015/2/27

Y1 - 2015/2/27

N2 - Epoxides from polyunsaturated fatty acids (PUFAs) are potent lipid mediators. In vivo stabilization of these epoxides by blockade of the soluble epoxide hydrolase (sEH) leads to anti-inflammatory, analgesic and normotensive effects. Therefore, sEH inhibitors (sEHi) are a promising new class of drugs. Herein, we characterized pharmacokinetic (PK) and pharmacodynamic properties of a commercially available potent sEHi 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU). Cell culture studies suggest its high absorption and metabolic stability. Following administration in drinking water to rats (0.2, 1, and 5. mg TPPU/L with 0.2% PEG400), TPPU's blood concentration increased dose dependently within the treatment period to reach an almost steady state after 8 days. TPPU was found in all the tissues tested. The linoleic epoxide/diol ratios in most tissues were dose dependently increased, indicating significant sEH inhibition. Overall, administration of TPPU with the drinking water led to systemic distribution as well as high drug levels and thus makes chronic sEH inhibition studies possible.

AB - Epoxides from polyunsaturated fatty acids (PUFAs) are potent lipid mediators. In vivo stabilization of these epoxides by blockade of the soluble epoxide hydrolase (sEH) leads to anti-inflammatory, analgesic and normotensive effects. Therefore, sEH inhibitors (sEHi) are a promising new class of drugs. Herein, we characterized pharmacokinetic (PK) and pharmacodynamic properties of a commercially available potent sEHi 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU). Cell culture studies suggest its high absorption and metabolic stability. Following administration in drinking water to rats (0.2, 1, and 5. mg TPPU/L with 0.2% PEG400), TPPU's blood concentration increased dose dependently within the treatment period to reach an almost steady state after 8 days. TPPU was found in all the tissues tested. The linoleic epoxide/diol ratios in most tissues were dose dependently increased, indicating significant sEH inhibition. Overall, administration of TPPU with the drinking water led to systemic distribution as well as high drug levels and thus makes chronic sEH inhibition studies possible.

KW - Caco-2 intestinal absorption

KW - EETs

KW - Eicosanoids

KW - Epoxy fatty acids

KW - Oxylipins

KW - Primary rat hepatocytes

KW - Soluble epoxide hydrolase

UR - http://www.scopus.com/inward/record.url?scp=84937061095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937061095&partnerID=8YFLogxK

U2 - 10.1016/j.prostaglandins.2015.06.005

DO - 10.1016/j.prostaglandins.2015.06.005

M3 - Article

C2 - 26117215

AN - SCOPUS:84949627199

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 1098-8823

ER -